This technical dossier examines published literature on cjc 1295 human trials, detailing the pharmacokinetics, receptor affinity, and physiological secretagogue mechanics of synthetic GHRH analogs. Designed exclusively for academic and laboratory researchers, this review compares modified GRF (1-29) variants with conjugated constructs to assist in experimental design.
This technical dossier examines published literature on cjc 1295 human trials, detailing the pharmacokinetics, receptor affinity, and physiological secretagogue mechanics of synthetic GHRH analogs. Designed exclusively for academic and laboratory researchers, this review compares modified GRF (1-29) variants with conjugated constructs to assist in experimental design.
CJC 1295 human trials initially evaluated the synthetic growth hormone-releasing hormone (GHRH) analog for its capacity to stimulate growth hormone (GH) secretion and elevate insulin-like growth factor 1 (IGF-1) levels. Clinical and preclinical investigations focused on its extended half-life compared to native GHRH, examining plasma stability, somatotroph receptor binding affinity, and downstream physiological markers in laboratory models.
In early clinical and preclinical models, researchers sought to establish whether structural modifications to the native 29-amino-acid GHRH sequence could prevent rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-IV). Published reports from initial human trials demonstrated that modified GHRH constructs successfully resisted metabolic degradation, producing sustained elevations in plasma GH and IGF-1 concentrations without disrupting basal feedback mechanisms. Explore PX1's full catalog of high-purity research peptides for comparative laboratory analysis.
Native GHRH (1-29), also known as sermorelin, exhibits an extremely brief plasma half-life of approximately 7 to 12 minutes due to swift cleavage by endogenous proteases. In contrast, cjc-1295 no dac research focuses on a tetrasubstituted peptide chain—specifically Modified GRF 1-29—where specific amino acid substitutions at positions 2, 8, 15, and 27 enhance resistance against DPP-IV enzymatic breakdown.
These structural modifications extend the biological half-life of CJC-1295 No DAC to approximately 30 minutes in animal models. This extended duration allows researchers to observe natural, pulsatile growth hormone release patterns from anterior pituitary somatotrophs, mimicking physiological GHRH bursts without causing permanent receptor downregulation or continuous baseline elevation. For detailed protocols on GHRH receptor stimulation, refer to our GHRH analogs overview.
The molecular structure of CJC-1295 No DAC consists of 29 amino acids: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Substitution of D-alanine at position 2 and glutamine at position 8 yields high chemical stability in aqueous solutions during in vitro assays.
Preclinical binding assays confirm that CJC-1295 binds selectively to the GHRH receptor (GHRHR), a G-protein-coupled receptor located on the cell surface of pituitary somatotrophs. Receptor activation triggers adenylate cyclase, raising intracellular cyclic adenosine monophosphate (cAMP) and initiating the transcription and exocytosis of stored growth hormone vesicles. Researchers studying receptor signaling pathways can review analytical methods in the PX1 research library.
When evaluating published literature, it is essential to distinguish between Modified GRF 1-29 and cjc-1295 with dac. The Drug Affinity Complex (DAC) modification incorporates a maleimido-propionic acid linker at the C-terminus, which covalently binds to circulating serum albumin upon administration. This bioconjugation extends the clearance half-life of the construct to approximately 6 to 8 days in non-human primates and clinical study subjects.
While CJC-1295 with DAC produces continuous, non-pulsatile elevations of baseline GH and IGF-1 over extended periods, CJC-1295 No DAC yields discrete, physiological pulses of GH release. The choice between these two research compounds depends on whether an experimental model requires steady-state endocrine stimulation or mimicking natural circadian hormone release profiles.
In published cjc-1295 no dac human trial reports and phase I clinical trials, single and multiple doses of GHRH analogs were evaluated for safety, tolerability, and secretagogue potency. Data indicated dose-dependent increases in mean plasma GH levels (elevated 2- to 10-fold) and baseline IGF-1 levels (elevated 1.5- to 3-fold) over 6 to 14 days of monitoring.
Importantly, preclinical investigations revealed that CJC-1295 preserved normal pituitary responsiveness to endogenous inhibitors like somatostatin. In animal models, glucose tolerance and thyroid-stimulating hormone (TSH) levels remained within baseline reference ranges during controlled administration periods, confirming high target specificity for somatotroph signaling cascades.
In laboratory research, CJC-1295 No DAC is frequently evaluated alongside alternative GHRH derivatives and growth hormone secretagogue receptor (GHSR) agonists to map somatotroph kinetics. Understanding these functional differences ensures accurate experimental design across cell cultures and animal models.
Compared to Sermorelin, CJC-1295 No DAC displays higher enzymatic stability and longer receptor activation windows. When contrasted with Tesamorelin—a trans-3-hexenoic acid modified GHRH analog—CJC-1295 No DAC offers a distinct kinetic profile for studying pulse frequency. Additionally, researchers often co-evaluate CJC-1295 No DAC with ghrelin receptor agonists like Ipamorelin to investigate dual-receptor secretagogue synergy.
Reliable scientific research requires pure, well-characterized peptides free from organic impurities, TFA salts, and bacterial endotoxins. PX1 Research enforces rigorous quality control standards across every manufactured lot to ensure experimental reproducibility across laboratory trials.
Every batch of PX1 research peptides undergoes full analytical verification, including High-Performance Liquid Chromatography (RP-HPLC) for purity determination (>99%) and Mass Spectrometry (LC-MS) for absolute identity confirmation. Furthermore, every lot is subjected to Chromogenic LAL assay testing to verify endotoxin levels remain strictly below <0.01 EU/mg. All products are USA-manufactured in GMP-compliant, ISO 17025 accredited facilities, backed by batch-specific Certificates of Analysis (COAs) and shipped same-day from inventory facilities in California and Arizona. Qualified academic institutions can access volume pricing through our wholesale lab account portal.
To preserve structural integrity and prevent hydrolytic degradation, lyophilized CJC-1295 No DAC must be stored at -20°C in a dry, dark environment prior to reconstitution. Lyophilized cakes stored under these conditions remain stable for up to 24 months.
For laboratory reconstitution, researchers should use sterile bacteriostatic water (0.9% benzyl alcohol) or sterile deionized water, allowing the solvent to run gently down the inner glass wall of the vial without aggressive agitation. Once dissolved, working solutions should be aliquoted into single-use microcentrifuge tubes to prevent degradation caused by repeated freeze-thaw cycles. Reconstituted solutions should be stored at 2°C to 8°C and evaluated within 21 to 30 days.
In vitro assays and animal studies frequently demonstrate that combining GHRH analogs with ghrelin mimetics yields synergistic growth hormone secretion far exceeding the additive sum of individual secretagogues. This phenomenon occurs because GHRH and ghrelin act via distinct intracellular second-messenger pathways within somatotrophs.
While GHRH activates the cAMP/PKA pathway via GHRHR, ghrelin mimetics stimulate the phospholipase C (PLC)/IP3 pathway via GHSR-1a. Combining CJC-1295 No DAC with ghrelin agonists triggers simultaneous calcium influx and cAMP accumulation, resulting in robust, physiological GH pulse amplitudes. Researchers exploring these dual-pathway dynamics can review comparative studies in our CJC-1295 vs Ipamorelin technical guide.
What do early cjc 1295 human trials demonstrate regarding growth hormone secretion?
Published cjc 1295 human trials demonstrate that synthetic GHRH analogs produce dose-dependent elevations in plasma growth hormone and downstream IGF-1 levels. Studies revealed an extended plasma half-life compared to native GHRH, maintaining natural secretory response mechanisms without adverse baseline hormone suppression.
What is the main finding in cjc-1295 no dac human trial literature?
Literature covering cjc-1295 no dac human trial data indicates that Modified GRF (1-29) enhances DPP-IV enzymatic resistance, extending the circulating half-life to roughly 30 minutes while preserving discrete, pulsatile release of endogenous growth hormone.
How does cjc-1295 no dac research differ from studies using native GHRH?
In cjc-1295 no dac research, the peptide contains four amino acid substitutions that protect it against rapid cleavage by dipeptidyl peptidase-4. Native GHRH has a half-life of 7–12 minutes, whereas CJC-1295 No DAC exhibits elevated biological stability during in vitro and in vivo assays.
What is the chemical difference between CJC-1295 No DAC and cjc-1295 with dac?
The primary difference lies in the addition of the Drug Affinity Complex (DAC). CJC-1295 with DAC contains a C-terminal maleimido-propionic acid linker that covalently binds to circulating serum albumin, extending its half-life to 6–8 days. CJC-1295 No DAC lacks this linker and has a half-life of ~30 minutes, preserving physiological pulse patterns.
Why is CJC-1295 No DAC preferred for pulsatile growth hormone research?
Researchers select CJC-1295 No DAC because its ~30-minute half-life allows somatotrophs to release growth hormone in natural, episodic bursts rather than inducing continuous, uninterrupted hormone elevation, preventing potential receptor desensitization.
How should lyophilized CJC-1295 No DAC be stored in the laboratory?
Lyophilized CJC-1295 No DAC should be kept at -20°C in a dry environment protected from light. Under these conditions, the powder remains stable for up to 24 months. Reconstituted liquid aliquots should be stored at 2°C to 8°C.
What analytical methods verify the purity of PX1 Research peptides?
PX1 Research verifies peptide purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity quantification (>99%) and Liquid Chromatography-Mass Spectrometry (LC-MS) for precise molecular mass identity verification.
How is CJC-1295 reconstituted for in vitro and preclinical research?
Reconstitution is performed using sterile bacteriostatic water or sterile deionized water. The diluent should be introduced down the side of the vial wall to prevent foam formation, followed by gentle swirling without shaking.
Can CJC-1295 No DAC be evaluated alongside ghrelin mimetics in research protocols?
Yes, preclinical studies frequently combine GHRH analogs like CJC-1295 No DAC with GHSR-1a agonists (such as Ipamorelin) to investigate dual-pathway somatotroph synergy, which leads to amplified intracellular cAMP and calcium signaling.
How does PX1 Research ensure low endotoxin levels in research peptide lots?
Every lot manufactured by PX1 Research undergoes rigorous Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin concentrations remain below <0.01 EU/mg, ensuring minimal baseline interference in cell culture and animal models.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.